Article Details

Lorlatinib vs Crizotinib in Advanced ALK-Positive NSCLC: 5-Year Outcomes From Phase III ...

Retrieved on: 2024-08-08 15:58:08

Tags for this article:

Click the tags to see associated articles and topics

Lorlatinib vs Crizotinib in Advanced ALK-Positive NSCLC: 5-Year Outcomes From Phase III .... View article details on hiswai:

Excerpt

Dr. Solomon has received honoraria from AstraZeneca and Roche/Genentech; institutional honoraria from Merck Sharp & Dohme, Pfizer, and Amgen; and ...

Article found on: ascopost.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up